公开(公告)号：US20230151002A1

公开(公告)日：2023-05-18

申请号：US17735283

申请日：2022-05-03

申请人： CHEMOCENTRYX, INC.

发明人： Pingchen FAN ,  Christopher W. LANGE ,  Rebecca M. LUI ,  Viengkham MALATHONG ,  Venkat Reddy MALI ,  Sreenivas PUNNA ,  Rajinder SINGH ,  Hiroko TANAKA ,  Yibin ZENG ,  Penglie ZHANG

IPC分类号： C07D471/04 ,  A61P37/02 ,  C07D519/00

CPC分类号： C07D471/04 ,  A61P37/02 ,  C07D519/00

摘要： The present disclosure provides, inter alia, Compounds of Formula (I)





or pharmaceutically acceptable salts thereof that are modulators of the C5a receptor. Also provided are pharmaceutical compositions and methods of use including the treatment of diseases or disorders involving pathologic activation from C5a and non-pharmaceutical applications.

公开(公告)号：US20230115912A1

公开(公告)日：2023-04-13

申请号：US17931801

申请日：2022-09-13

申请人： CHEMOCENTRYX, INC.

发明人： Pingchen FAN ,  Christopher W. LANGE ,  Viengkham MALATHONG ,  Venkat Reddy MALI ,  Sreenivas PUNNA ,  Hiroko TANAKA ,  Yibin ZENG ,  Penglie ZHANG

IPC分类号： A61K31/437 ,  A61P37/00 ,  A61P35/00 ,  A61P9/00

摘要： The present disclosure provides, inter alia, Compounds of Formula (I) or pharmaceutically acceptable salts thereof that are modulators of the C5a receptor. Also provided are pharmaceutical compositions and methods of use including the treatment of diseases or disorders involving pathologic activation from C5a and non-pharmaceutical applications.

公开(公告)号：US20220127272A1

公开(公告)日：2022-04-28

申请号：US17331750

申请日：2021-05-27

申请人： CHEMOCENTRYX, INC.

发明人： Junfa FAN ,  Antoni KRASINSKI ,  Christopher W. LANGE ,  Rebecca M. LUI ,  Jeffrey P. McMAHON ,  Jay P. POWERS ,  Yibin ZENG ,  Penglie ZHANG

IPC分类号： C07D487/04 ,  A61K51/04 ,  G01N33/574

摘要： Compounds having formula I, or pharmaceutically acceptable salts, hydrates or N-oxides thereof are provided and are useful for binding to CXCR7, and treating diseases that are dependent, at least in part, on CXCR7 activity. Accordingly, the present invention provides in further aspects, compositions containing one or more of the above-noted compounds in admixture with a pharmaceutically acceptable excipient.

公开(公告)号：US20210308119A1

公开(公告)日：2021-10-07

申请号：US17219172

申请日：2021-03-31

申请人： ChemoCentryx, Inc.

发明人： James CAMPBELL ,  Israel CHARO ,  Thomas SCHALL ,  Rajinder SINGH ,  Yibin ZENG ,  Penglie ZHANG

IPC分类号： A61K31/4709 ,  C07K16/24 ,  C07K16/28 ,  A61K31/4402 ,  A61P1/00

摘要： Provided herein are compositions, methods and kits for treating inflammatory bowel disease (IBD) such as Crohn's disease and ulcerative colitis in a mammal in need thereof. The method include administering to a subject with IBD a combination therapy containing a therapeutically effective amount of a chemokine receptor 9 (CCR9) inhibitor compound and a therapeutically effective amount of an anti-IL-23 antibody. Also provided herein is a kit containing the CCR9 inhibitor compound and anti-IL-23 antibody.

公开(公告)号：US20190270761A1

公开(公告)日：2019-09-05

申请号：US16357889

申请日：2019-03-19

申请人： CHEMOCENTRYX, INC.

发明人： Pingchen FAN ,  Antoni KRASINSKI ,  Venkat Reddy MALI ,  Shichang MIAO ,  Sreenivas PUNNA ,  Yang SONG ,  Valentino J. STELLA ,  Yibin ZENG ,  Penglie ZHANG

IPC分类号： C07F9/6558 ,  C07F9/59 ,  C07D211/60 ,  A61K31/451 ,  A61K31/675 ,  A61K31/496 ,  A61K45/06

摘要： Compounds are provided to modulate the C5a receptor. The compounds have the following Formula (I): including stereoisomers and pharmaceutically acceptable salts thereof, wherein R1, R2 and R3 are as defined herein. Methods associated with preparation and use of such compounds, as well as pharmaceutical compositions comprising such compounds, are also disclosed.

公开(公告)号：US20230339851A1

公开(公告)日：2023-10-26

申请号：US18186265

申请日：2023-03-20

申请人： CHEMOCENTRYX, INC.

发明人： Hiufung CHU ,  Pingchen FAN ,  Yandong LI ,  Viengkham MALATHONG ,  Jay POWERS ,  Hiroko TANAKA ,  Yibin ZENG ,  Penglie ZHANG

IPC分类号： C07D231/14 ,  C07D261/18 ,  C07D317/60 ,  C07D237/24 ,  C07D309/10 ,  C07D275/03 ,  C07D319/12 ,  C07D307/24 ,  C07D207/16 ,  C07D309/06 ,  C07D493/08 ,  C07D295/195 ,  C07D239/28 ,  C07D307/16 ,  C07D265/30 ,  C07D309/28 ,  C07D309/08 ,  C07D211/60 ,  C07D207/22 ,  C07D233/90 ,  C07D317/66 ,  C07D211/62 ,  C07D335/02 ,  C07C311/44 ,  C07D307/68 ,  C07D213/81 ,  C07D471/08

CPC分类号： C07C311/44 ,  C07D207/16 ,  C07D207/22 ,  C07D211/60 ,  C07D211/62 ,  C07D213/81 ,  C07D231/14 ,  C07D233/90 ,  C07D237/24 ,  C07D239/28 ,  C07D261/18 ,  C07D265/30 ,  C07D275/03 ,  C07D295/195 ,  C07D307/16 ,  C07D307/24 ,  C07D307/68 ,  C07D309/06 ,  C07D309/08 ,  C07D309/10 ,  C07D309/28 ,  C07D317/60 ,  C07D317/66 ,  C07D319/12 ,  C07D335/02 ,  C07D471/08 ,  C07D493/08 ,  C07C2601/02 ,  C07C2601/04 ,  C07C2601/08 ,  C07C2601/14 ,  C07C2601/16 ,  C07C2601/18 ,  C07C2602/08 ,  C07C2602/18 ,  C07C2602/42

摘要： Provided are sulfonamide compounds having formula (I):





or a pharmaceutically acceptable salt thereof, wherein R, R1, R2, R3, R4 and the subscripts n and m have the meanings provided in the specification. The compounds are useful for treating diseases and conditions associated with CXCR6 activity.

公开(公告)号：US20210130347A1

公开(公告)日：2021-05-06

申请号：US17071056

申请日：2020-10-15

申请人： CHEMOCENTRYX, INC.

发明人： Pingchen FAN ,  Christopher W. LANGE ,  Rebecca M. LUI ,  Darren J. McMURTRIE ,  Ryan J. SCAMP ,  Ju YANG ,  Yibin ZENG ,  Penglie ZHANG

IPC分类号： C07D471/04

摘要： Compounds are provided that are useful as immunomodulators. The compounds have the Formula (I) including stereoisomers and pharmaceutically acceptable salts thereof, wherein R2a, R2b, R3, R3a, R4, R6, R7, R8, A, Z, X1 and n are as defined herein. Methods associated with preparation and use of such compounds, as well as pharmaceutical compositions comprising such compounds, are also disclosed.

公开(公告)号：US20210130325A1

公开(公告)日：2021-05-06

申请号：US17071077

申请日：2020-10-15

申请人： CHEMOCENTRYX, INC.

发明人： Pingchen FAN ,  Christopher W. LANGE ,  Rebecca M. LUI ,  Darren J. McMURTRIE ,  Ryan J. SCAMP ,  Ju YANG ,  Yibin ZENG ,  Penglie ZHANG

IPC分类号： C07D401/14 ,  C07D403/14 ,  C07D405/14 ,  C07D401/12 ,  C07D487/10

摘要： Compounds are provided that are useful as immunomodulators. The compounds have the Formula (I) including stereoisomers and pharmaceutically acceptable salts thereof, wherein R2a, R2b, R3, R3a, R4, R6, R7, R8, A, Z, X1 and n are as defined herein. Methods associated with preparation and use of such compounds, as well as pharmaceutical compositions comprising such compounds, are also disclosed.

公开(公告)号：US20190144389A1

公开(公告)日：2019-05-16

申请号：US16173914

申请日：2018-10-29

申请人： CHEMOCENTRYX, INC.

发明人： Pingchen FAN ,  Rebecca M. LUI ,  Venkat Reddy MALI ,  Rajinder SINGH ,  Yibin ZENG ,  Penglie ZHANG

IPC分类号： C07D211/60 ,  A61K31/451 ,  A61K45/06

摘要： Compounds are provided to modulate the C5a receptor. The compounds have the following Formula (I): including stereoisomers and pharmaceutically acceptable salts thereof, wherein R1, R2 and R3 are as defined herein. Methods associated with preparation and use of such compounds, as well as pharmaceutical compositions comprising such compounds, are also disclosed.

公开(公告)号：US20180250293A1

公开(公告)日：2018-09-06

申请号：US15820008

申请日：2017-11-21

申请人： CHEMOCENTRYX, INC.

发明人： Penglie ZHANG ,  Andrew M.K. PENNELL ,  John J. Kim WRIGHT ,  Wei CHEN ,  Manmohan R. LELETI ,  Yandong LI ,  Lianfa LI ,  Yuan XU ,  Mark M. GLEASON ,  Yibin ZENG ,  Kevin Lloyd GREENMAN

IPC分类号： A61K31/496 ,  A61K45/06 ,  A61K31/5377 ,  C07D471/04 ,  C07D487/04

CPC分类号： A61K31/496 ,  A61K31/5377 ,  A61K45/06 ,  C07D471/04 ,  C07D487/04

摘要： Compounds are provided that act as potent antagonists of the CCR1 receptor, and have in vivo anti-inflammatory activity. The compounds are generally aryl piperazine derivatives and are useful in pharmaceutical compositions, methods for the treatment of CCR1-mediated diseases, and as controls in assays for the identification of competitive CCR1 antagonists.